The following consensus is up to date for Dr. Martens as at 25th November 2021
| H1 FY22 6 months ended 30 September 2021 |
FY22 Year ending March 2022 |
FY23 Year ending March 2023 |
|
|---|---|---|---|
| Revenue | £358m | £905m | £1,052m |
| EBITDA | £88.5m | £258m | £305m |
| PBT | £61.0m | £198m | £239m |
| EPS | 4.8p | 15.7p | 19.0p |
The above FY22 and FY23 consensus is the mean average of forecasts gathered from 8 out of 8 covering sell-side analysts.
H1 FY22 consensus is the mean average of forecasts gathered from 7 out of 8 covering sell-side analysts.
Legal disclaimer
These financial forecasts are not prepared nor endorsed by Dr. Martens in any way. Dr. Martens has no current or pending duty to verify any individual estimates, and assumes no responsibility to update, revise or otherwise comment on any of the information contained in these forecasts. It should be noted that financial forecasts are, by definition, forward looking, and are therefore subject to various risks and uncertainties which are subject to change at any time.
